Liu Shudong, Jing Fei, Yu Chunxiao, Gao Ling, Qin Yejun, Zhao Jiajun
Department of Endocrinology, Provincial Hospital Affiliated to Shandong University, Jinan, China; Department of Endocrinology, Shandong Rongjun General Hospital, Jinan, China.
Department of Endocrinology, Provincial Hospital Affiliated to Shandong University, Jinan, China.
PLoS One. 2015 May 1;10(5):e0124951. doi: 10.1371/journal.pone.0124951. eCollection 2015.
Our previous study found that thyroid-stimulating hormone promoted sterol regulatory element-binding protein-2 (SREBP-2) expression and suppressed AMP-activated protein kinase (AMPK) activity in the liver, but it was unclear whether there was a direct link between TSH, AMPK and SREBP-2. Here, we demonstrate that the 5-aminoimidazole-4-carboxyamide ribonucleoside (AICAR)-induced activation of AMPK directly inhibited the expression of SREBP-2 and its target genes HMGCR and HMGCS, which are key enzymes in cholesterol biosynthesis, and suppressed the TSH-stimulated up-regulation of SREBP-2 in HepG2 cells; similar results were obtained in TSH receptor knockout mice. Furthermore, AMPK, an evolutionally conserved serine/threonine kinase, phosphorylated threonine residues in the precursor and nuclear forms of SREBP-2, and TSH interacted with AMPK to influence SREBP-2 phosphorylation. These findings may represent a molecular mechanism by which AMPK ameliorates the hepatic steatosis and hypercholesterolemia associated with high TSH levels in patients with subclinical hypothyroidism (SCH).
我们之前的研究发现,促甲状腺激素可促进肝脏中固醇调节元件结合蛋白2(SREBP-2)的表达,并抑制肝脏中AMP激活的蛋白激酶(AMPK)的活性,但促甲状腺激素、AMPK和SREBP-2之间是否存在直接联系尚不清楚。在此,我们证明5-氨基咪唑-4-甲酰胺核苷(AICAR)诱导的AMPK激活直接抑制了SREBP-2及其靶基因HMGCR和HMGCS的表达,这两种基因是胆固醇生物合成中的关键酶,并抑制了促甲状腺激素刺激的HepG2细胞中SREBP-2的上调;在促甲状腺激素受体敲除小鼠中也获得了类似结果。此外,AMPK是一种进化上保守的丝氨酸/苏氨酸激酶,可磷酸化SREBP-2前体和核形式中的苏氨酸残基,并且促甲状腺激素与AMPK相互作用以影响SREBP-2的磷酸化。这些发现可能代表了一种分子机制,通过该机制AMPK可改善亚临床甲状腺功能减退症(SCH)患者中与高促甲状腺激素水平相关的肝脏脂肪变性和高胆固醇血症。